Investors don't yet realize today's announcement about HSA is clear signal Ampion will be approved
If Ampio were uncertain to any degree that Ampion may not be approved, they certainly would not commit to an agreement for the supply of enough HSA to provide Ampion treatment for the entire OAK population.
There are so many clues that it again brings us back to why doesn't Ampio rally in the face of bullish news that would rocket any stock.
It is the plain and simple fact that they have no big name banker endorsing their shares. Absent a big banker, investors will always be very reluctant to take a position until some major event occurs and this will keep shares undervalued.
Comparison to ACAD and AEGR indicate AMPE shares should be selling over $50 today making AMPE an extremely undervalued company.
Use this opportunity to accumulate a sure thing.
Ampio is a sure thing and they don't come any better risk to reward ratio.
Thanks for the compliment, but it takes one to know one.
In my strong opinion, you have found the biggest winner of the next decade in the entire market that investors and traders will begin to center their focus on in just a few months or less.
Can't give you names, but suffice to say that some of the best known biotech investors are trying to quietly pick up all the stock they can get their hands on here in the 7's 8's and 9's without putting shares up in price. The big buyers don't want shares to rise until they get enough for themselves.
If you buy and hold for at least three years, you will become very wealthy.
Question on the Oct 29th FDA meeting. Is it possible to get an FDA approval of Ampion from this meeting without having to undertake a larger Phase 3 trial??? Just trying to see if it was POSSIBLE, although I think probably un-likely
I understand the Phase III will need to be done in all cases. But that the FDA can either expedite a BLA after the trial or consider a BLA concurrently with the Phase III trial If they approve a breakthrough drug designation request. These options may be being discussed at the Oct 29 meeting.